Contemporary management of low-risk bladder cancer

lthough pTa low-grade papillary bladder tumors are at low risk for progression, one-third will recur within 5 years. With this in mind, Falke and Witjes discuss the clinical pathway of low-risk bladder cancer based on current guidelines, from diagnosis using classification systems to treatment options and recommended follow-up.